0001209191-19-031530.txt : 20190520
0001209191-19-031530.hdr.sgml : 20190520
20190520183555
ACCESSION NUMBER: 0001209191-19-031530
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190516
FILED AS OF DATE: 20190520
DATE AS OF CHANGE: 20190520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KAZANCHYAN ANNA
CENTRAL INDEX KEY: 0001369219
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36621
FILM NUMBER: 19840375
MAIL ADDRESS:
STREET 1: 933 MAMARONECK AVENUE
STREET 2: SUITE 103
CITY: MAMARONECK
STATE: NY
ZIP: 10543
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Foamix Pharmaceuticals Ltd.
CENTRAL INDEX KEY: 0001606645
STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
BUSINESS PHONE: 97289316233
MAIL ADDRESS:
STREET 1: 2 HOLZMAN ST.
STREET 2: WEIZMANN SCIENCE PARK
CITY: REHOVOT
STATE: L3
ZIP: 76704
FORMER COMPANY:
FORMER CONFORMED NAME: Foamix Ltd.
DATE OF NAME CHANGE: 20140428
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2019-05-16
0
0001606645
Foamix Pharmaceuticals Ltd.
FOMX
0001369219
KAZANCHYAN ANNA
C/O FOAMIX PHARMACEUTICALS LTD.
2 HOLTZMAN STREET
REHOVOT
L3
ISRAEL
1
0
0
0
Ordinary Shares
2019-05-16
4
A
0
28195
0.00
A
55955
D
Ordinary Shares
2019-05-20
4
S
0
10600
2.61
D
45355
D
This security represents restricted share units. Each restricted share unit represents a contingent right to receive one ordinary share of the issuer.
The ordinary shares underlying this restricted share unit award vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2019.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.57 to $2.68 inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form 4.
/s/ Mutya Harsch as attorney-in-fact for Anna Kazanchyan
2019-05-20